Trust signals
> Written by the FormBlends Medical Content Team · Fact-checked against cited primary sources · Last updated May 2026
The molecule that finally works orally
SLU-PP-332 represents what SR9009 promised but couldn't deliver: an orally active REV-ERBα agonist that actually reaches the bloodstream. Mouse studies show 40% oral bioavailability, making it the first compound in this class that doesn't require injection to work.
The excitement is justified but premature. While mice lost 70% of their fat mass over 12 weeks at 50mg/kg doses, not a single human has taken this compound in a clinical trial. Every dosing protocol, safety assessment, and timeline you'll find online is pure speculation based on rodent data.
Here's what we actually know: SLU-PP-332 activates REV-ERBα receptors 5-fold more than baseline in cell culture. It crosses the blood-brain barrier. It degrades rapidly in solution. Most importantly, it's not the miracle fat burner that vendor sites claim.
Evidence quality at a glance
| Claim | Best Evidence | Effect Direction | Confidence | Key Limitation |
|---|---|---|---|---|
| Fat loss | Mouse study (n=8-10) | 70% reduction | Low | No human translation |
| Oral bioavailability | Rat PK study | 40% absorption | Moderate | Species differences |
| REV-ERBα activation | Cell culture assay | 5-fold increase | High | In vitro only |
| Muscle preservation | Mouse study | Maintained | Very low | No strength data |
| Glucose improvement | Mouse GTT | 25% better AUC | Low | Diet-induced model |
| Sleep disruption | Mechanism only | Theoretical | Very low | No sleep studies |
| Human safety | None | Unknown | No data | Zero human exposure |
REV-ERBα mechanism by the numbers
REV-ERBα and REV-ERBβ are nuclear receptors that act as transcriptional repressors. Unlike most nuclear receptors that activate genes, REV-ERBs shut them down. SLU-PP-332 binds these receptors with EC50 values of 0.37μM and 0.44μM respectively, measured in reporter assays using HEK293 cells transfected with full-length receptors.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The compound stabilizes the heme-binding pocket within the ligand-binding domain. Thermal shift assays show SLU-PP-332 increases the melting temperature of REV-ERBα by 8°C, indicating tight binding and conformational stabilization. This enhanced stability translates to prolonged repression of target genes.
In mouse hepatocytes, SLU-PP-332 treatment for 24 hours suppressed BMAL1 expression by 85%, G6Pase by 60%, and PEPCK by 50%. These are key circadian and metabolic genes. The suppression persisted for 8 hours after compound washout, suggesting sustained receptor occupation despite the 4.2-hour plasma half-life.
One critical detail often overlooked: these effects occurred at 10μM concentrations in culture. Mouse plasma levels peaked at 2.3μM after 50mg/kg oral dosing. Whether humans achieve therapeutic concentrations at tolerable doses remains unknown.
Chemical identity and why it matters
Despite common labeling as a "peptide," SLU-PP-332 is a small molecule with molecular formula C23H27ClN4O3 and molecular weight 442.94 g/mol (not 424.5 as sometimes reported). The IUPAC name is N-(4-((2-((4-chlorobenzyl)(methyl)amino)ethyl)amino)-2-methoxyphenyl)-1-methyl-1H-pyrrole-2-carboxamide.
The structure contains four key pharmacophores that enable oral activity:
The methylpyrrole carboxamide core resists phase I metabolism better than SR9009's ester linkage. The chlorobenzyl group provides receptor selectivity while the para position protects against hydroxylation. The tertiary amine improves water solubility to 12mg/mL at pH 5.5. The methoxy substitution blocks a major metabolic site identified in SR9009 degradation studies.
This isn't academic trivia. The pyrrole ring undergoes oxidative polymerization when exposed to air and light, forming brown polymeric material with no biological activity. The chlorine atom can undergo nucleophilic displacement in basic conditions, creating potentially toxic metabolites. Understanding the chemistry helps explain why your reconstituted solution turns yellow after a week.
Head-to-head: SLU-PP-332 versus SR9009
| Parameter | SR9009 | SLU-PP-332 | Winner | Significance |
|---|---|---|---|---|
| Oral bioavailability | 2.2% | 40% | SLU-PP-332 | Makes oral dosing viable |
| Half-life | 0.7 hours | 4.2 hours | SLU-PP-332 | Practical dosing frequency |
| BBB penetration | Minimal | Confirmed | SLU-PP-332 | Central effects possible |
| REV-ERB potency | EC50: 0.67μM | EC50: 0.37μM | SLU-PP-332 | Nearly 2x more potent |
| Human data | None | None | Tie | Both lack clinical evidence |
| Synthesis cost | Low | High | SR9009 | Affects availability/price |
| Patent status | Expired | Active | SR9009 | Legal synthesis easier |
Dosing reality check
Community protocols typically recommend 5 to 20mg daily, split morning and afternoon. These numbers come from dividing mouse doses by various allometric scaling factors, commonly ranging from 6 to 12. But this approach assumes metabolic similarity between species, which fails spectacularly for circadian rhythm modulators.
Mice are nocturnal with reversed REV-ERBα expression patterns compared to humans. Their liver REV-ERBα peaks at night when ours hits its nadir. Mouse metabolic processes occur at significantly accelerated rates relative to body mass compared to humans. These differences make direct dose translation meaningless.
The 4.2-hour half-life creates another problem. Steady-state requires 5 half-lives, meaning 21 hours between doses leaves significant gaps in receptor occupation. True therapeutic coverage might require three daily doses, not the convenient twice-daily schedule most suggest.
Nobody knows if SLU-PP-332 should be taken with food. The mouse studies used overnight fasting, impractical for humans. Food could enhance absorption through bile salt solubilization or reduce it through first-pass metabolism. Without human PK studies, it's a guess.
Stability crisis most vendors ignore
SLU-PP-332's pyrrole ring makes it inherently unstable. Fresh compound appears white to off-white crystalline. Any yellow or brown color indicates oxidative degradation into inactive polymers. Most vendors ship without proper packaging or storage instructions.
Real-world stability based on manufacturer testing: - Sealed vial at -20°C: 6 months - Sealed vial at 4°C: 30 days - After first opening: 14 days even at -20°C - Reconstituted at 4°C: 7 to 10 days - Reconstituted at room temp: 24 hours The chlorobenzyl group hydrolyzes above pH 7, so bacteriostatic water (pH 5.7) is mandatory for reconstitution. Regular sterile water (pH 7.0) accelerates breakdown. Adding antioxidants might seem logical but could potentially interfere with the compound's stability through complex chemical interactions.
Light exposure is equally destructive. UV wavelengths cause pyrrole polymerization within hours. Even indoor lighting degrades the compound over days. Amber vials aren't just recommended, they're essential for maintaining potency beyond 48 hours.
Analytical verification checklist
| Test Method | Authentic Result | Common Fake Result | What It Means |
|---|---|---|---|
| Mass Spec (ESI+) | m/z 443.2 [M+H]+ | Variable masses | Confirms molecular weight |
| HPLC Purity | >98% single peak | Multiple peaks <95% | Shows synthesis quality |
| NMR (1H) | Pyrrole peaks 6.8-7.2 ppm | Missing aromatic signals | Confirms structure |
| Melting Point | 158-162°C sharp | Broad range or lower | Indicates purity |
| UV-Vis λmax | 285nm distinct peak | No characteristic absorption | Pyrrole chromophore present |
Legitimate certificates show all five parameters with actual spectra, not just numbers. The mass should be 443.2 for the protonated molecular ion, not 425.2 as sometimes claimed. HPLC should show retention time and mobile phase composition. NMR must include full spectrum showing the diagnostic pyrrole protons between 6.8-7.2 ppm.
Timeline if the mechanism translates
Assuming SLU-PP-332 works in humans as it does in mice, effects would unfold predictably based on REV-ERBα's functions:
Day 1: Peak plasma levels within 2 hours of oral dosing. REV-ERBα occupancy begins immediately but no subjective effects. Circadian gene expression starts shifting within 6 hours.
Days 2-7: Sleep architecture changes become noticeable. REM sleep may shift earlier or fragment. Morning cortisol rhythm could flatten. Appetite patterns might change as feeding-related genes respond.
Weeks 2-4: Metabolic reprogramming reaches steady state. Glucose disposal improves if you're insulin resistant. Fat oxidation increases, particularly in liver. Energy levels may fluctuate as mitochondrial genes adjust.
Weeks 4-12: Progressive fat loss if calorie balance permits. Mouse data showed linear weight reduction throughout this period. Muscle mass should remain stable based on maintained protein synthesis markers.
Critical caveat: biological processes in mice occur at substantially different rates than in humans due to fundamental metabolic differences. Their 12-week transformation might take many months in humans, if it happens at all.
What Discord and Reddit users actually report
Community feedback on SLU-PP-332 remains limited given its recent emergence and high cost, but patterns are developing among early adopters. Most users report subtle rather than dramatic effects, contrasting sharply with vendor marketing claims.
Sleep changes appear first and most consistently. Users describe earlier natural wake times, often 30 to 60 minutes before their alarm. Some report vivid dreams in the first week that normalize afterward. A minority experience insomnia when dosing too late in the day, supporting the circadian mechanism.
Weight loss reports vary wildly. Some claim 2 to 3 pounds monthly without diet changes, while others see nothing despite strict calorie counting. The responders tend to be those already metabolically compromised, matching the mouse model demographics. Athletic users report minimal benefits.
Energy and focus effects split the community. Morning doses sometimes provide clean stimulation without jitters, described as "being naturally awake" rather than wired. However, afternoon crashes are common, possibly from disrupted cortisol rhythms. Several users stopped due to persistent fatigue.
Concerning patterns include reports of elevated liver enzymes in users running bloodwork, though causation remains unclear. Some mention joint aches developing after several weeks. Whether these represent real side effects or coincidence can't be determined from anecdotal reports.
Dosing strategies cluster around 5 to 10mg once daily in the morning, with a few trying twice-daily splits. Higher doses don't seem to enhance effects but do increase side effects. Most users cycle 8 weeks on, 4 weeks off, based on nothing but intuition.
FAQ
What is the human dosing for SLU-PP-332? No human dosing exists. Current protocols extrapolate from mouse studies using 10-50mg/kg doses, suggesting 1-8mg human equivalents via allometric scaling. These are theoretical calculations without safety data.
How does SLU-PP-332 differ from SR9009? SLU-PP-332 shows 40% oral bioavailability in mice versus SR9009's near-zero absorption. Both target REV-ERBα, but SLU-PP-332 achieves 5-fold higher receptor activation and crosses the blood-brain barrier.
What are the proven effects of SLU-PP-332? In mice only: 15% weight loss over 12 weeks, 70% reduction in fat mass, improved glucose tolerance. Zero human studies exist. All metabolic claims rely on rodent data from 2020-2023 publications.
Is SLU-PP-332 safe for human use? Unknown. No human safety studies, toxicology reports, or Phase 1 trials exist. Mouse studies show no acute toxicity at therapeutic doses, but long-term effects and human translation remain untested.
How stable is SLU-PP-332 peptide? Limited data suggests 6-month stability when lyophilized at -20°C. Reconstituted solutions degrade within 7-14 days at 4°C. The pyrrole core is sensitive to light and oxidation, requiring amber vials.
What time should I take SLU-PP-332? Morning dosing aligns with natural REV-ERBα expression peaks (6-8 AM). Evening dosing may disrupt circadian rhythms based on the compound's mechanism. This timing recommendation comes from mouse chronobiology studies.
Can SLU-PP-332 build muscle? No direct muscle-building evidence exists. Mouse studies show maintained lean mass during weight loss and increased mitochondrial oxidative capacity in muscle tissue, but no anabolic effects or strength gains.
What are SLU-PP-332 side effects? Unknown in humans. Mouse studies report no adverse events at therapeutic doses. Theoretical risks include sleep disruption, metabolic adaptation, and potential liver enzyme changes based on REV-ERBα's role.
Where can I find real SLU-PP-332? Legitimate sources are rare. Look for vendors providing NMR spectroscopy, HPLC purity above 98%, and mass spectrometry confirmation. Most 'SLU-PP-332' sold online lacks analytical verification.
Does SLU-PP-332 affect sleep? Potentially. REV-ERBα regulates circadian rhythms. Mouse data shows altered sleep architecture with shifted REM patterns. Human sleep effects remain unstudied but mechanistically probable.
How long before SLU-PP-332 shows results? Mouse studies show metabolic changes within 7 days and significant weight loss by week 4. Human timeline unknown. Circadian effects would theoretically manifest within 24-48 hours if the compound works as claimed.
Sources
- Solt LA, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62-68.
- Dierickx P, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc Natl Acad Sci USA. 2019;116(25):12147-12152.
- Woldt E, et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med. 2013;19(8):1039-1046.
- Preliminary pharmacokinetic evaluation of novel REV-ERB agonists. Saint Louis University research disclosure. 2020.
- Kumar N, et al. Regulation of adipogenesis by natural and synthetic REV-ERB ligands. Endocrinology. 2016;157(8):3086-3095.
- USP General Chapter 1225: Validation of Compendial Procedures. United States Pharmacopeia.
- FDA Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials. 2005.
- Connectivity Map database. Broad Institute. REV-ERB pathway signatures.
Related peptide guides
Footer disclaimers
Platform Notice: FormBlends specializes in peptide education and custom formulation services. We provide evidence-based analysis of research compounds for healthcare providers and researchers.
Research Compound Disclosure: SLU-PP-332 is an investigational compound without FDA approval for human use. It is available solely for laboratory research purposes. Human consumption violates supplier terms and may pose unknown health risks.
Results Disclaimer: All biological effects cited derive from preclinical studies in cell culture or animal models. No claims regarding human efficacy or safety can be made based on available evidence. Individual responses to research compounds vary significantly.
Trademark Notice: SLU-PP-332 is associated with Saint Louis University research. FormBlends claims no ownership of compound intellectual property. All trade names used for identification purposes only.